Tag Archives: Nuzyra

Specialty Pharmacy News Roundup: November 2023

The following company announcements are just a few of the specialty pharmacy company activities from this month. Subscribe to AMI’s Specialty Pharmacy Database to stay up to date on company and industry trends

NUZYRA Continues to be the Primary Driver for Paratek Pharmaceuticals’ Growth

The FDA approved Paratek’s supplemental New Drug Application (sNDA) for the oral-only dosing regimen of NUZYRA® for the treatment of adults with Community-Acquired Bacterial Pneumonia (CABP)